A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Status:
Recruiting
Trial end date:
2024-11-04
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to
17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.